Boston, MA -- (SBWIRE) -- 12/11/2013 -- Mexico's encouraging macroeconomic growth prospects, business-friendly environment and improving pharmaceutical regulatory regime have made it an increasingly attractive market to multinationals. Apart from the ageing population and the increasing incidence of chronic diseases, the government's commitment to improve its healthcare services is another fundamental factor driving market growth. In addition, its unparalleled policies in market accessibility have made Mexico an important hub for multinationals to enter other Latin American countries.

Headline Expenditure Projections

- Pharmaceuticals: MXN176.00bn (US$13.38bn) in 2012 to MXN191.71bn (US$15.10bn) in 2013; +8.9% in local currency terms and +12.8% in US dollar terms. Forecast increased from Q413 due to positive industry developments.
- Healthcare: MXN961.30bn (US$73.09bn) in 2012 to MXN1,046.29bn (US$82.39bn) in 2013; +8.8% in local currency terms and +12.7% in US dollar terms. Forecast increased from Q413 due to changes in macroeconomic forecasts.

View Full Report Details and Table of Contents

Risk/Reward Rating: Mexico scores 60.6 in BMI's Pharmaceutical and Healthcare Risk/Reward Rating (RRR), making it the fifth-most attractive pharmaceutical market in America. We have reweighted the RRR components this quarter to improve the tool and adjusted scores for all markets in our Pharmaceuticals & Healthcare reports.

Key Trends And Developments

- In September 2013, Mexican President Enrique Pena Nieto unveiled the fiscal reform proposal to bolster government revenue. We highlight the exemption of medicines to VAT and the creation of universal social security will further improve the long-term outlook of the country's pharmaceutical market..
- In August 2013, UN Comtrade reported that medicine imports in Mexico reached US$4.6bn in 2012.
- In August 2013, Cofepris started a consultancy service to discourage self-medication and unfair competition, according to the commissioner of Cofepris, Mikel Arriola. As part of the programme, Cofepris will open 10,000 clinics at pharmacies in the country, which will provide about 250,000 daily consultations to people who are not able to attend other medical care centres.
. - In July 2013, Mexican pharmaceutical company Genomma Lab reported that sales increased 22.1% year-on-year to MXN2.53bn (US$200.39mn) in Q213 (ended June 2013).
- In July 2013, Novo Nordisk announced that its new basal insulin (degludec) designed for the treatment of Type I and Type II diabetes is commercially available in Mexico

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Healthcare research reports at Fast Market Research

You may also be interested in these related reports:

- Slovenia Pharmaceuticals & Healthcare Report Q1 2014
- Latvia Pharmaceuticals & Healthcare Report Q1 2014
- Croatia Pharmaceuticals & Healthcare Report Q1 2014
- Netherlands Pharmaceuticals & Healthcare Report Q1 2014
- Australia Pharmaceuticals & Healthcare Report Q1 2014
- Nigeria Pharmaceuticals & Healthcare Report Q1 2014
- Oman Pharmaceuticals & Healthcare Report Q1 2014
- Central America Pharmaceuticals & Healthcare Report Q1 2014
- Poland Pharmaceuticals & Healthcare Report Q1 2014
- Argentina Pharmaceuticals & Healthcare Report Q1 2014